The CARDS Trial

Patients with Type 2 diabetes have a higher risk of developing cardiovascular disease compared to the general population, but can this risk be reduced by lowering cholesterol?

That is the question that is addressed by CARDS, the first ever primary prevention study of cholesterol lowering specifically in patients with Type 2 diabetes who have not experienced a cardiovascular event. A total of 2838 patients between 40-75 years old were involved.

CARDS was anticipated to complete in June 2005. As the trial objectives were met early, it was stopped in June 2003.

The exciting results from CARDS were first presented at the prestigious American Diabetes Association congress on 6 June 2004. Watch the results presented by the Executive Committee by visiting the healthcare professional or press office pages.

CARDS results media release - issued 6 June 2004 CARDS results media backgrounder CARDS results presentation CARDS overview for general public

CARDS was jointly sponsored by Diabetes UK, the Department of Health and Pfizer.